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The application of genome-wide association studies and next-generation sequencing has had 
limited success in identifying causal genes for complex diseases. Bipolar disorder is one such 
disease whose aetiology has not been elucidated despite the application of these technologies. 
Candidate gene prioritisation offers a solution to limit the vast amount of possible candidate 
genes produced from the combination of data sources. Current prioritisation tools rely heavily on 
previous data and thus do not perform well for poorly characterised diseases such as bipolar 
disorder. Here we have developed Data Integrated Genetics, DIG, a new candidate gene 
prioritisation tool designed specifically for complex genetic diseases. Given a user-specified 
disease query, DIG initially data-mines literature, linkage, homolog and sequence data to create 
a pool of possible candidates. The tool filters out likely false positives by removing pseudogenes. 
A unique data integration method is used to rank the remaining list of genes. Additionally, 
ranking is validated by tissue expression and single nucleotide polymorphism annotation. DIG 
exhibited comparable performance to existing tools when evaluated with four complex diseases. 
Eight novel genes were identified when DIG was applied to bipolar disorder, of which the 
Huntingtin gene poses as an exciting avenue for new aetiology research. The ease of use and 
realistic number of possible candidates given in the DIG results make this tool highly useful for 
research application in the study of complex genetic diseases. DIG is freely available from 
http://www.cbio.uct.ac.za/DIG.  
 




Identifying causal genetic factors is an essential step in our understanding and subsequent 
prevention and treatment of complex disorders (Sun et al., 2009). The advent of genome-wide 
association studies (GWAS) and next generation sequencing (NGS) has offered us the ability to 
explore genomic variations in affected individuals. However, there are several factors that 
complicate the ability of these technologies to confirm if variants are false positives or genuinely 
causal genes (Oti et al., 2011). The vast amount of data produced by GWAS and NGS is one such 
factor. Intricate computational analysis serves as a solution to reduce the number of likely 
candidates for further investigation into the true differences between case and control patients.  
 
1.1 What is a complex disorder? 
 
Complex disorders are caused by a combination of genetic and environmental factors. These can 
occur as discrete traits, such as diabetes, as well as continuous traits, such as the psychiatric 
disorders bipolar disorder and schizophrenia. Complex disorders do not obey the standard 
Mendelian patterns of inheritance as they are polygenic, whereby a combination of variants in 
many genes contribute to the manifestation of disease (Pritchard, 2001).  
There are currently two central hypotheses to explain the genetic contribution needed for a certain 
complex phenotype to manifest. The first, the “common disease/common variant” (CD/CV) 
hypothesis postulates that a disease phenotype is likely to result from the aggregate effect of 
variants present at high frequencies in human populations (Lander, 1996). Recently, the 
alternative “common disease/rare variant” (CD/RV) hypothesis was proposed, as studies on 
common variants have failed to explain a large portion of the heritability of complex disorders 
(Schork et al., 2009), deemed as the “missing heritability”. The CD/RV hypothesis states that 
multiple rare variants with large effect sizes are the main determinants of heritability of the 
complex phenotypes (Bodmer and Bonilla, 2008). The missing heritability could, however, also 
be explained by common variants with small effect sizes, such that GWAS are underpowered to 
detect the slightly significant differences between case and control samples.  
Minor individual contributions from a large set of genes, as well as the reduced probability of 
finding rare susceptibility genes, creates a challenge to determine true causal variants. Methods to 
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prioritise candidate genes, thereby limiting the number of investigated genes, are the first step for 
investigating the aetiology and genetic cause of complex diseases. 
 
1.2 Bipolar disorder as a case study 
 
By the year 2020, it is estimated that psychiatric disorders will account for 15% of the total 
burden of all diseases (Merikangas et al., 2009). Bipolar disorder (BPD) is one of the major 
contributors of this statistic. Unfortunately, very little knowledge is known about the aetiology of 
this disorder. BPD presents a niche in which to apply new techniques that aim to uncover genetic 
determinants of complex disorders. 
According to the Diagnostic and statistical manual of mental disorders (DSM, 4th edition, 1994), 
BPD is diagnosed with the presence of one or more manic or mixed episodes, usually 
accompanied with one or more major depressive episodes. The lifetime prevalence of BPD varies 
from 0% to 2.1% among different populations (Merikangas et al., 2009). There is a strong genetic 
component to the susceptibility to BPD, with heritability estimated at 87% (Smoller and Finn, 
2003). Concordance rate for monozygotic twins is around 70% (Cardno et al., 1999) and relative 
risk for siblings of affected individuals is estimated at 7.9 times that of the general population 
(Lichtenstein et al., 2009).  
Large numbers of genetic studies, including several GWAS, have been carried out to identify 
BPD susceptibility loci (Goes et al., 2012; Greenwood et al., 2013; Meier et al., 2012). Functional 
neuroimaging studies in BPD have identified dysfunction in key neural circuits, including the 
amygdale, limbic nuclei, prefrontal cortex, the anterior cingulate, the medial thalamus, and 
regions of the basal ganglia (Carlson et al., 2006). 
 
Despite the abundance of research, there has been no convincing insight into understanding the 
aetiology of BPD. New methods in finding susceptibility genes are required to propose novel 
genes to investigate for involvement in pathogenesis of this disorder. BPD is therefore an ideal 
disease model to test the functionality and application of a newly designed candidate gene 
prioritisation approach. If successful, the identification of novel candidate genes could aid 
geneticists in the elucidation of the biological mechanism responsible for the BPD phenotype. 
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1.3 Candidate gene prioritisation 
 
Candidate gene prioritisation is the identification of putative genes that show the most promising 
role in disease aetiology from a large list of genes (Tranchevent et al., 2010). This approach 
greatly reduces the number of genes to consider in the study of a complex disorder and ranks them 
according to the likelihood of being involved in disease pathogenesis (Sun et al., 2009). Most 
current prioritisation strategies use the ‘guilt-by-association’ concept wherein novel candidate 
genes will be those that are similar to genes already known to be associated with the given disease 
phenotype (Tranchevent et al., 2010).  
 
Bioinformatic approaches, which allow for computational analysis of relevant information from a 
variety of different data sources, are critical in effective candidate gene prioritisation. Numerous 
bioinformatic tools are available to data-mine high-throughput results from NGS, GWAS and 
other functional data sources. Using statistical and computational tools, data-mining of 
experiments and public web databases can be combined to give an unbiased candidate gene list for 
a specific complex disorder (Tiffin et al., 2006).  
This in silico approach to candidate gene prioritisation was first implemented in the Genes to 
Diseases (G2D) tool (Perez-Iratxeta et al., 2005), the methodology of which has subsequently 
been modified and used in a range of other bioinformatic programs. All of these programs have 
specific inputs and advantages, as well as having certain fallbacks and bias.  
 
1.4 Review of existing prioritisation tools 
 
With the exception of Candid (Hutz et al., 2008) and Endeavour (Aerts et al., 2009), most 
previous candidate gene prioritisation tools have focused on integrating a very limited number of 
data resources. A selection of these tools is presented below, explaining the basis of each method. 
Tools were chosen to represent the broad range of data sources used, and are analysed with 
respect to their ability to find novel complex genes for poorly characterised diseases. G2D and 
PosMed (Yoshida, et al., 2009) are based on text-mining available data sources; Candid and 
Endeavour both use multiple data sources but with a genome-wide method versus a guilt-by-
association approach, respectively, and Genewanderer (Kohler, et al., 2008) prioritises genes 
based on protein-protein interactions. 
 
 




Perez-Iratxeta et al. (2005) are accredited for the design of Genes to Diseases (G2D) as the first 
formalised candidate gene prioritisation tool. This program prioritises genes related to a disease 
by text-mining OMIM (http://www.omim.org/), MEDLINE (http://www.ncbi.nlm.nih. 
gov/pubmed) and Ref-Seq (http://www.ncbi.nlm.nih.gov/refseq/ ) databases for a list of weighted 
MeSH C terms (disease category) and Gene Ontology (GO) terms. An OMIM identifier (ID) and 
candidate locus are used as inputs, with all genes within the locus ranked for involvement in 
disease aetiology.  
 
Should users be interested in more than one loci, common within analysis of complex diseases, 
the search would have to be individually repeated for each additional loci, and results manually 
combined. The genomic range specified is limited to a certain range due to search methods being 
computational intensive. Should a disease not be specified by an OMIM ID, the authors advise the 
use of an ID for a similar disease. The use of functional annotation specified by GO is dependent 
on the quality and completeness of such annotation, and also shows bias against novel genes that 
may have little or no annotation. In addition, G2D does not appear to be maintained, since the last 




The PosMed tool (Yoshida, et al., 2009) utilises the General and Rapid Association Study Engine 
(GRASE) as a method to text mine a set of more than 17 million medical and biological 
documents in relation to the user-defined disease query. GRASE returns a set of documents 
related to the disease and the genes found within these documents. Users are also required to 
specify a genomic region as a set of candidates. The set of documents is subsequently evaluated 
for statistical significance among the candidate genes based on co-citations in documents, protein–
protein interactions (PPI), ortholog genes or co-expression data. Only genes that receive a p-value 
less than 0.01 are finally ranked according to their likelihood for involvement in the queried 
disease. This makes PosMed unique in that it returns a limited list of ranked candidate genes. 
 
PosMed allows users to input either a disease name or a list of terms related to the disease. 
Bornigen et al. (2012) found that the set of keywords specified by the user strongly influences 
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results returned by the tool. Like G2D, PosMed is limited in analysing a single linked genomic 
locus at a time. Since PosMed relies solely on curated information, the methodology shows heavy 





Candid (Hutz et al., 2008) is one of the few existing tools that makes use of several different types 
of data sources, including literature, protein domains,  gene conservation and expression 
information, PPI, linkage and association analysis and an option to add custom data. Options to 
search the whole genome or just specified loci are available. Input can be given by either 
keywords or training genes. This tool was specifically designed to analyse complex genetic 
diseases; however, users define their own weighting criteria for the various data sources, meaning 
that a thorough understanding of the queried disease is necessary in order to gain valuable and 
reliable output. Data sources not incorporated into this tool include homolog information, 




Endeavour (Aerts et al., 2009) is another tool that incorporates multiple data sources. This tool 
prioritises a set of user-specified candidate genes according to characteristics found over-
represented in a training set, defined by the user, as compared to the complete genome. Gene 
function, gene expression, protein sequence, mutant phenotypes and PPI are all assessed.  
 
For poorly characterised diseases, such as bipolar disorder, training genes may either not be 
available or show any strong overrepresentation of the same characteristics. Users effectively limit 
the candidate search space by having to provide the genes in which to search for an association. 
Since Endeavour relies solely on the guilt-by-association principle, candidates that differ in 










Like Endeavour, Genewanderer (Kohler, et al., 2008) requires users to specify a set of training 
genes. A chromosomal locus of interest is also required as an input. This tool builds a gene 
interaction network from the training genes using HPRD (http://www.hprd.org/ ), BIND 
(http://bind.ca), BioGrid (http://www.thebiogrid.org/ ), IntACT (http://www.ebi.ac.uk/intact/), DIP 
(http://dip.doe-mbi.ucla.edu) and STRING (http://www.string-db.org/ ). All genes within the locus 
are evaluated for proximity to this network.  Users may choose between four different proximity 
measures; however, the random walk method performed best during benchmarking. This approach 
starts at a given training node and transitions to a randomly selected neighbour in order to 
calculate the probability of reaching a candidate node. 
 
Genewanderer operates solely on PPI data, and thus can only be used for genes that have their 
interactions mapped, which may be rare for novel genes. Network-based prioritisation is greatly 
dependent on the quality of interaction data. Although multiple interaction databases are 
incorporated, they are still incomplete. Electronic annotations may also be a source of unreliable 
interactions and therefore produce false positives. 
 
Existing tools, such as the ones described above, place high emphasis on previous knowledge. For 
poorly characterised diseases, this requirement limits the success of prioritisation. 
 
1.5 Problem statement 
 
Besides the restricted application of current tools to under-studied diseases, bioinformatic 
solutions have not been appropriately utilised. Candidate gene prioritisation has been used in 
several studies of complex disorders; however, most of this research is specific to the disease 
under study and not been made into a usable tool that can be applied to other complex genetic 
diseases. Sun et al. (2009) performed candidate prioritisation for schizophrenia by manually 
combining data from literature, linkage, association and expression sources. They then assessed 
625 different weight matrices to evaluate the optimal weights at which to combine the sub-scores 
for each candidate gene that allowed for the highest ranking of a set of training genes. This 
research selected 502 genes for follow up study in a schizophrenia cohort. This exhaustive 
approach is not suitable for wide-scale use and has limited clinical validity since many possible 
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candidates remain. Other studies, similar to the above example, have essentially created a 
redundancy of bioinformatic work since the results can only be applied to the specific disorder 
studied.  
 
Following from these arguments, there is a need for a new, generic tool to be designed that can be 
applied to any complex genetic disease. The tool should incorporate a maximum number of data 
resources as possible, thereby utilising the vast amount of genetic data that has been produced 
specifically within the last decade. This tool must attempt to avoid the problems identified in 
current tools that limit their success for complex disorders. 
 
1.6 System considerations 
 
The different approaches used in a variety of existing tools were analysed to identify the common 
advantages and pitfalls to consider in the design of a new prioritisation tool. These factors include 
the bias to well-studied genes, information that is available on homologs, dependence on database 
quality and validation of the ranking of genes. 
 
Tools that require a training set (genes that have already been associated with the disease), rely on 
previous biological characterisation of the trait, and can create a bias in selecting candidate genes. 
These tools are limited in that it is assumed that the undiscovered disease genes will be consistent 
with what is already known about a disease and/or its genetic basis, which is not true, necessarily 
(Hutz et al., 2008). Such a method is particularly poor for studying diseases where few or no 
disease genes are associated with the phenotype or where the known disease genes account for 
only a small percentage of cases presenting with the disease, such as in phenotypes with reduced 
penetrance or variable expressivity (George et al., 2006). 
The same bias is created when a tool relies heavily on scientific literature resources, as these do 
not include uncharacterised genes. Contrary to this, sequence-based tools reward genes for their 
putative involvement in disease regardless of how frequent research has been conducted to 
associate the gene to a particular phenotype (Adie et al., 2005). 
 
A further consideration is the inclusion of homolog information, especially for diseases that are 
not well understood or whose mechanism of action has yet to be discovered. Data on animal 
 
~ 15 ~ 
 
models of the disease is important, since data are collected under strictly controlled conditions not 
possible in human studies (Simmons, 2008). 
 
Tools that prioritise genes based on functional annotation rely on the accuracy and content of the 
databases they gather information from. This means that data on a query disease must already 
reside in the database (Hutz et al., 2008). The experimental quality of associations and 
interactions documented in a database determines the accuracy of the gene prioritisation, 
especially for network-based prioritisation. Experimental evidence, such as from Yeast 2 Hybrid 
assays, and manual curation, such as used in the SwissProt database (http://www.uniprot.org/), is 
more reliable than inferred interactions or electronic curation. Higher weighting should be given 
to sources that are more reliable, whist at the same time candidates should not be penalised due to 
missing information. 
 
Once all data sources have been integrated to give an overall score per gene, ranking of the genes 
needs to be evaluated for accuracy. Benchmark tests are needed to assess the tool’s ability to find 
relationships between a given disease and the genes within a queried genome. Benchmarking must 
be performed with diseases that already have a list of genes confidently known to be associated 
with the phenotype (Perez-Iratxeta et al., 2005).  
 
All of the above system considerations need to be incorporated into a new gene prioritisation tool 
to undertake the growing bioinformatic demands of analysing complex genetic diseases. Once a 
new tool has been designed and validated, it may be used to prioritise poorly-characterised 
diseases, the results of which can then be clinically tested on patient samples.  
 
The burden of complex genetic diseases on public healthcare systems will only subside if we first 
understand the aetiology and biological mechanisms of these phenotypes. GWAS and NGS 
technologies are generating overwhelming amounts of data that need to be processed in order to 
extract significant results. Candidate gene prioritisation is the link between this data and the 
application of these findings to clinical genetic research.   
 
This paper continues on to describe the development of Data Integrated Genetics (DIG), which 
was designed according to the system considerations discussed above.  It is an innovative tool to 
integrate data for any human genetic disease from a variety of data sources. We aim to allow 
human geneticists to effectively use the vast amounts of freely-available data so as to focus their 
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experiments on the most probable causative genes, ultimately leading to the discovery of disease 









 Implementation:  
o To integrate as many freely-available data sources as possible into a usable, web-
based tool 
 Validation:  
o To validate the tool’s performance with several complex disease datasets 
o To compare the tool’s performance to existing prioritisation tools 
 Application: 









In the design of DIG, a combination of different data sources and web tools were used in order to 
take advantage of the vast amount of freely-available data. DIG does not require the entry of any 
training disease genes, but instead the candidate search space is created from information that is 
automatically retrieved from databases for genes and chromosomal bands already known to be 
associated with the queried disease from literature, linkage and homolog data. DIG then integrates 
these three sources as well as a number of other data sources to evaluate the likelihood of each of 
the genes being involved in the query disease. The DIG script was written in Python 2.75 and the 
website was implemented in Cherrypy, with all major browsers supported. Supplementary figure 
1 shows the total workflow of the program. The full python scripts are available from 
http://www.cbio.uct.ac.za/DIG/source. Please contact the author for access credentials. 
 
2.1 Query expansion 
 
Firstly, DIG uses the Disease Ontology (DO) (Schriml et al., 2012) to expand the search query 
entered by the user. The DO database combines disease names and identifiers from MeSH 
(Nelson et al., 2004), ICD (Ayme et al., 2010), OMIM and NCI (Sioutos et al., 2007) to create a 
directed acyclic graph for over 8000 inherited, developmental and acquired human diseases. This 
hierarchy maps the direct and indirect relationships between diseases. 
 DIG uses a GET Request (http://docs.python-requests.org/en/) to extract the DO unique ID for 
the user query term. The returned DO ID is then used in a second GET Request to access the 
REST Application Program Interface (API) used by the DO database (http://www.disease-
ontology.org/search?adv_search=True&operator=AND&field-1=name&value-1='+keyword). 
This returns a JSON packet containing all the metadata for the queried term, including parents, 
children, synonyms, definition, name and alternative IDs. Regular expressions are used to build 
lists of synonyms, parent and child terms from the JSON data. 
 
2.2 Literature search 
 
Pubmed literature is the first data source used to extract genes related to the user-defined disease. 
The Entrez EUtilities (Sayers, 2008) suite of tools is used to access the Pubmed API. EUtilities 
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use a fixed URL syntax to query the National Centre for Biotechnology Information (NCBI) 
databases. The user is required to supply their email address in order to use this service.  
 
A search is created by concatenating all expanded keywords from DO into a string with the 
deliminator ‘OR’ to separate different keywords. A query array of terms is created by slicing this 
global concatenated query term into substrings of 150 characters or less. This is done to comply 
with the character limit set on the NCBI API. 
 
From EUtilities, the ESearch tool is used to find all Pubmed articles matching the query string(s). 
ESearch iterates through all elements in the query array, retrieving a list of Pubmed article IDs 
matching the query. The Pubmed IDs are added to a set in order to automatically remove 
redundancy. Links to each of these articles is created by concatenating the Pubmed home URL 
with the Pubmed ID. 
 
A mapping file ‘gene2pubmed’, available from the Entrez file transfer protocol (ftp) site 
(ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/), is used to find all human genes mentioned within an 
article from the list of matching Pubmed IDs. All genes are added to the pool of possible 
candidate genes. 
 
A literature score is calculated for each of the genes identified in the literature search. This overall 
literature score is calculated as shown by Equation 1.  
 
   𝑙𝑖𝑡𝑆𝑐𝑜𝑟𝑒 =  
number of disease articles the gene appeared in
𝑡𝑜𝑡𝑎𝑙 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑚𝑎𝑝𝑝𝑒𝑑 𝑡𝑜 ℎ𝑢𝑚𝑎𝑛 𝑔𝑒𝑛𝑒𝑠
           (1) 
 
 
2.3 Linkage data 
 
Linkage data is collected from a tool called aBandApart (van Vooren et al., 2007). This tool text-
mines MEDLINE abstracts relating to cytogenetic bands for an overrepresentation of a queried 
biomedical concept. In this way, aBandApart is able to link large genomic aberrations to genetic 
diseases, syndromes and dysmorphology in human development. The relationship between band 
and concept is quantified by calculating a p-value for the observed number of papers that are 
associated to a band and that mention the query concept or one of its synonyms. 
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WebDriver, from the python module Selenium (https://pypi.python.org/pypi/selenium), designed 
to emulate an instance of the Moxilla Firefox browser, is used to submit a form to aBandApart. 
The main term returned from DO is used for the linkage query, unless this returns no linkage data, 
where upon the parent term is used.  
 
XPath, from the lxml python module (https://pypi.python.org/pypi/lxml), is then used to extract 
the cytogenetic bands and their corresponding p-values from the returned extensible markup 
language (xml) data. The user is requested to supply a significance cut-off (default = 0.05) to then 
filter the returned bands.  
 
A file of all human genes mapped to a cytogenetic band was downloaded from BioMart 
(http://www.ensembl.org/biomart/martview/2cfef8ac90eebc767b87136f3e3c8e03). This local file 
is used to extract all genes designated by the filtered bands. Genes from the same band are 
assigned the same p-value and score as per Equation 2. These genes are added to the candidate 
gene pool. 
 
     𝑙𝑖𝑛𝑘𝑆𝑐𝑜𝑟𝑒 = 1 − 𝑃𝑣𝑎𝑙𝑢𝑒             (2) 
 
2.4 Homolog data 
 
Homolog data is extracted from a text-mining tool called Genie (Fontaine et al., 2011). Using the 
MEDLINE, Gene and HomoloGene databases from NCBI (http://www.ncbi.nlm.nih.gov/), Genie 
allows for the prioritisation of all genes from a given species related to a biomedical topic. This 
tool assesses the significance of the abstracts that contain genes associated to the target model 
organism for their relevance to the chosen biomedical concept. The false discovery rate (FDR) for 
each gene-to-topic relationship is then calculated.  
The DIG user is asked to choose a model organism from a list in which to search for homolog 
data. They may select from the following organisms: Mus musculus (mouse), Rattus norvegicus 
(rat), Drosophila melanogaster (fruit fly), Sus scrofa (pig), Macaca mulatta (rhesus macaque), 
Oryctolagus cuniculus (rabbit) and Pan troglodytes (chimpanzee). The default choice is Mus 
musculus.  
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DIG posts an HTTP Request to Genie using the python module Mechanize 
(https://pypi.python.org/pypi/mechanize/). The script then sets the biomedical concept as the main 
term returned by DO and the target species as the taxonomic ID of the species chosen by the user. 
A regular expression is subsequently used to search the returned request data for the homolog 
gene identifiers and their corresponding FDRs.  
The Entrez Gene identifiers of the model organisms are converted to their corresponding Ensembl 
Gene identifiers using local mapping files from BioMart. A second local BioMart file then maps 
these IDs to Ensembl human homologs. These are added to the candidate gene pool. A homolog 
score is calculated for each human gene as described by Equation 3. 
 
     ℎ𝑜𝑚𝑜𝑆𝑐𝑜𝑟𝑒 = 1 − 𝐹𝐷𝑅             (3) 
 
Model organism genes may occasionally map to multiple human homologs; these genes all 
receive the same FDR related to the model organism source. 
 
2.5 Sequence data 
 
Data from a previous tool, PROSPECR (Adie et al., 2005), was used to obtain information about 
gene sequences. The authors found that disease genes share certain properties in gene structure as 
compared to genes not involved in disease. The disease characteristics include longer gene and 
protein length, larger number of exons, well conserved mouse and rat homologs, secretion of the 
gene product (validated by the presence of a signal peptide), longer 3’ untranslated regions (UTR) 
and larger distance to the nearest neighbouring gene. Using this information, PROSPECR uses an 
alternating decision tree algorithm to classify genes as likely to be involved in hereditary disease 
or otherwise.   
 
A file containing pre-computed PROSPECR scores for 22, 240 genes was downloaded 
(http://www.genetics.med.ed.ac.uk/prospectr/.) DIG searches this local file for all matches to the 
candidate gene pool, returning their PROSPECR scores or “None” if the gene is not found.  
 
From all of the above sources, genes will have a minimum of one sub-score and a maximum of 
four. If a gene had only one data source of evidence, this single sub-score would be used as an 
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estimate of the total integrated score. Should a gene have more than one sub-score, a method to 
combine the sub-scores is necessary. 
 
2.6 Data integration 
 
The aim of data integration is to achieve a balance between limiting false positives and the 
avoidance of penalising genes with few sub-scores due to incomplete databases. Owing to the 
different quality and amount of data available from different information sources, an integrated 
score that assigns different weights to each sub-score is needed. However, this weighting will be 
dependent on the research conducted on each disease queried, and thus a standardised weighting 
will not be possible. It is thus necessary to calculate a weight matrix in response to the data 
retrieved for the user’s disease. 
 
If we assume that each sub-score is an unbiased, independent estimate of the gene’s association to 
the disease, we can then apply a linear regression model to the data such that a higher integrated 
score represents a higher likelihood for a gene’s involvement in disease aetiology.  The relative 
contribution of each sub-score to the reliability of such a measure can be described by a weight 
matrix that accounts for the different types of data available for the disease. To prevent over-
fitting of the data to this linear regression model, the sum of all weights must equal one (Equation 
4).  
 
    𝑤𝑙𝑖𝑡 + 𝑤𝑙𝑖𝑛𝑘 +  𝑤ℎ𝑜𝑚𝑜 + 𝑤𝑠𝑒𝑞 = 1              (4) 
 




introduced. The denominator is the sum of weights for all non-null sub-scores. This constant is 
then multiplied by the product of each sub-score and its weight as demonstrated by Equation 5. 
For genes that have scores for all four values, this constant will equal one, with the integrated 
score simply calculated as the sum of the sub-scores multiplied by their respective weights. 
However, for genes that have missing values, this proportion will serve to readjust the weights of 
non-null sub-scores so that Equation 4 is still satisfied.  
 
  𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑 𝑠𝑐𝑜𝑟𝑒 =  
1
∑ 𝑤𝑖
(𝑤𝑙𝑖𝑡𝑠1 + 𝑤𝑙𝑖𝑛𝑘𝑠2 + 𝑤ℎ𝑜𝑚𝑜𝑠3 + 𝑤𝑠𝑒𝑞𝑠4)           (5) 
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Variance of a sub-score is used as an approximation for the reliability of each data source as an 
estimator of whether a gene is causal for the disease or not. All genes in the candidate pool must 
have at least some relation to the disease in order to have been considered a candidate. Thus, a 
higher variance for non-null values of a sub-score is seen as decreased confidence in the data 
source, and hence a smaller weight is assigned for the sub-score to achieve the most accurate 
integrated score.  
 
The mean, 𝐸𝜒𝑖, is calculated from all non-null values for a given sub-score, and then used to 
calculate the variance (𝐸𝜒𝑖 − 𝑠𝑖)
2 of each gene from this expected value. The variance for a sub-
score (𝜎𝑖
2) is equal to the sum of variances for all genes divided by the number of genes, 𝑗, as 
described by Equation 6. Since variance is inversely proportional to the weight of the sub-score, 





  𝐴𝑝𝑝𝑟𝑜𝑥𝑖𝑚𝑎𝑡𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒𝑠𝑢𝑏−𝑠𝑐𝑜𝑟𝑒 = 𝜎𝑖





            (6) 
 
In order to comply to Equation 4, where the sum of all non-null weights must equal to one, we 
calculate an absolute weight by diving the relative weight for the sub-score by the sum of relative 
weights for all sub-scores as shown in Equation 7. 
  










              (7)  
 
Variance of each sub-score will then be used to calculate the most appropriate weighting for each 




Once integration is completed, candidate genes are then filtered to extract false positives and to 
limit results to the most promising genes, generating output as quickly as possible whilst not 
losing valuable information. 
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2.7.1 Number of data sources 
 
A sub-score of zero is still considered an observation and thus increases the confidence of a score 
as compared to a null sub-score. With more null sub-scores, the confidence for a gene decreases 
and the possibility for a gene to be significant purely by chance increases. For this reason, genes 
that have fewer than three sources of evidence are automatically filtered out by DIG. This is to 
eliminate the effects from false positives that arise from the three data sources used to build the 
candidate gene pool, since all genes should theoretically have a sequence score. If fewer than 15 
candidates are returned, then the filter is automatically adjusted to include genes with two or more 
sources of evidence. 
 
2.7.2 Pseudogene data 
 
A second method to eliminate false positives is via pseudogene screening. A comprehensive list of 
pseudogenes was created by extracting and combining Ensembl IDs using BioMart’s 
IG_C_pseudogene, IG_J_pseudogene, IG_V_pseudogene, polymorphic_pseudogene, 
processed_pseudogene, pseudogene, TR_J_pseudogene and TR_V_pseudogene datasets. This 
resulted in a total of 15 524 genes.  
 
DIG reads this file to find any of the candidate genes in the list of known pseudogenes. Should a 




Ordered lists are created in which genes are ranked in decreasing order according to one of the 
sub-scores. Global ranking is performed using the integrated score as a sorting method. To 
account for genes that share the same score, the rankings of tied scores are replaced with the top 
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2.9 Data validation 
 
To further highlight false positives, two validation strategies are implemented. Tissue annotation 
is included in the output of DIG so that the user may critically determine if expression of the gene 
is plausible to be involved in the aetiology of the disease. Genes that are expressed in the same 
tissues that are differentially regulated in the disease are good candidates and boost confidence for 
the gene to be a possible candidate.  
 
Single nucleotide polymorphisms (SNPs) from dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) are 
also mapped to the top ranking candidate genes, along with the region within the gene that the 
SNP is found in, being either intronic, exonic, upstream, downsteam, or within the regulatory 
region. This was achieved by downloading a local version of dbSNP. The file was then annotated 
with SNPEffect (http://snpeff.sourceforge.net/) and dbNSFP (Liu et al., 2013). Fields were 
extracted to make a new local file containing rs ID, gene name, SNP effect, SIFT 
(http://sift.jcvi.org/) and PolyPhen (http://genetics.bwh.harvard.edu/pph2 /dokuwiki/) scores for 




Figure 1. Diagram depicting the overall methodology employed by DIG to prioritise candidate genes. 
Literature, linkage and homolog data sources are used to collect a large pool of possible candidates which 
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2.10 Performance measures 
 
2.10.1 Evaluation of DIG before and after variance matrix application 
 
In order to evaluate the accuracy of DIG, four well-studied complex diseases, all of whom have 
known associated genes, were tested. Supplementary table 1 shows the training genes used for 
breast cancer, type 2 diabetes mellitus, asthma and Alzheimer’s disease that were taken from Hutz 
et al. (2008). Linkage cut-off was set to 0.05 and Mus musculus used as the animal model for all 
diseases tested. Indicators used in Bornigen et al. (2012) were then used to assess the performance 
of DIG.  
 
STATA12 was used to calculate the area under the curve (AUC) for receiver-operating 
characteristic (ROC) curves for each disease to evaluate global accuracy. Sensitivity of the tool, 
also known as the true positive rate (TPR), was calculated at 5 per cent, 10 per cent and 30 per 
cent for each disease. Response rate for a disease, defined as the number of training genes 
included in the DIG output, was also evaluated.  
 
A one by four weight matrix with equal weights for each score was initially used. Performance 
indicators were calculated for all sub-scores and for the integrated score by comparing the DIG 
output of ranked genes to the list of training genes. Analysis of the diseases was repeated using 
the variance weight matrix as per Equation 6. Differences in performance measures were 
calculated for rankings made before and after the application of the new matrix.  
 
2.10.2 Comparison of DIG to existing candidate gene prioritisation tools 
 
Trachevent et al., (2010) created a decision tree that categorises existing candidate prioritisation 
tools according to input used and outputs produced. Using this tree, tools most similar to DIG 
were selected to compare performance statistics. Endeavour and PosMed were selected since both 
tools use keywords as an input to assign ranks to candidate genes.  Other tools were excluded due 
to their use of training genes as an input or because genes were simply selected and not ranked 
according to likelihood of disease involvement. 
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2.11 Tool application to BPD 
 
DIG was finally run for bipolar disorder. “Bipolar disorder” was entered as the query keyword 
and Mus musculus set as the animal model. The linkage cut-off value was set to a more lenient 0.1 
since most positional studies show weak genetic signals for linkage data (Serretti and Mandelli, 
2008). 
 
Ranked genes were then evaluated from a comprehensive list of training genes for BPD attained 
from Serretti and Mandelli (2008) and Chen, et al. (2009). The top 41 genes were manually 
evaluated for involvement in BPD aetiology by reading associated literature and assessing 
pathways, Gene Ontology (GO) terms, protein-protein interactions and searching Genetics 
Association Database (http://geneticassociationdb.nih.gov/cgi-bin/index.cgi) for each candidate.  
 




DIG utilises hypertext mark-up language (html) form submission to gain input about the queried 
disease from the user, followed by dynamic interaction to gain parameters for filter cut-off values 
before displaying the output. DIG is freely available from http://www.cbio.uct.ac.za/DIG/; no 
registration is required. A tutorial document is available on the site, detailing the input needed and 
answering common questions. 
 
3.1 Implementation: The user’s experience 
 
Users are required to input the name of the disease they wish to query, a linkage significance cut-
off value and also supply a valid email address as required for the Entrez ESearch tool. A list of 
seven radio buttons allows the user to select the animal model in which to search for homolog 
information. Once the user has entered all required input data and submitted the form, a loading 
page is displayed until job completion. Time taken for each job is dependent of the extent of 
research conducted on the disease. A minimum time of three minutes is expected, but can extend 
up to 10 minutes if analysing well-documented diseases.  
 
Thereafter, a line graph displaying the distribution of integrated scores for all ranked genes is 
displayed. The user is asked to choose the number of genes to display in the results. The output 
page displays summary statistics for the gene prioritisation with a table showing ranked genes 
displayed below this.  
 
For each gene, sub-scores for literature, linkage, homology and sequence data is shown alongside 
the relative rankings within each of the categories. Tissues in which the gene is expressed are 
listed. Any non-synonymous SNPs found in the gene are listed, with their corresponding gene 
region and effect. SIFT and Polyphen scores for each of these SNPs are also displayed if 
available. The number of data sources found for the gene is presented, having a maximum of 4. 
The integrated score for the candidate is highlighted at the end of the table row. 
 
Links to Pubmed articles that were used to rank the gene in the literature sub-score are presented 
for easy navigation to relevant articles. This allows the user to perform quick evaluation of the 
results and to perform a follow up literature search. Links to the Ensembl gene sequence allow for 
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further analysis of the candidate and may help geneticists in their design of polymerase chain 
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3.2 Validation: Performance statistics 
 
3.2.1 Accuracy of variance weight matrix 
 
The variance weight matrix used in the DIG methodology was compared to the use of equal 
weighting for sub-scores by analysing performance indicators for four reasonably well 
characterised diseases. This was to evaluate the impact of using variance as a reliability measure 
on the accuracy of DIG in ranking candidate genes. Higher values for indicators indicate greater 
accuracy. TPR5, TPR10 and TPR30 represent the probability of finding true positive results (i.e., 
training genes) when only analysing the top 5%, top 10% and top 30% of the ranked genes 
respectively. AUC measures the probability that DIG will rank any one of the training genes 
higher than the rest of the genome. A minimum score of 0.5 for AUC means that tool ranks 
training genes randomly, whereas a maximum score of 1.0 indicates that training genes are always 
ranked first.  Response rate describes the number of training genes ranked in the output results of 
the tool. For each training gene filtered out of the results, response rate decreases proportionally to 
the total number of training genes used. For example 42 breast cancer training genes were used, of 
which 30 were ranked by DIG, denoting a response rate of 30 ÷ 42 × 100 = 71.4%. 
 
A marginal improvement in performance was seen when using the variance weighting system as 
compared to the use of equal weights in most categories. However, the new matrix did not 
improve the response rate achieved by DIG. Table 1 shows the percentages achieved for 
performance indicators before and after application of the variance matrix to DIG.  
 
 
Table 1. Comparison of performance indicators for DIG using equal weights for all sub-scores as 
compared to the use of variance weighting system described in the tool methodology. 
 
Weighting TPR5% TPR10% TPR30% AUC Response rate % 
Equal weights 51.2 52.8 69.0 0.539 64.2 
Variance weights 58.6 68.7 79.2 0.556 64.2 
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3.2.2 Comparison to existing tools 
 
The performance of DIG was compared to Endeavour and PosMed. It was found that both DIG 
and PosMed returned far fewer candidate genes than Endeavour did. Table 2 shows that DIG 
outperformed both the existing tools in TPR5 and TPR10; however, Endeavour displayed the best 
performance in all other categories. Further analysis of these results is discussed later. 
 
 
Table 2. Comparison of performance indicators for DIG, Endeavour and PosMed. Best performing tool for 
each indicator highlighted in bold. 
Tool TPR5% TPR10% TPR30% AUC Response rate % 
DIG 58.6 68.7 79.2 0.556 64.2 
PosMed 4.7 11.9 23.8 0.560 50.0 
Endeavour 26.2 42.9 90.5 0.820 100.0 
 
3.3 Application: Findings for novel BPD associations 
 
The analysis of BPD resulted in 822 genes being ranked, with a maximum integrated score of 
0.999 and minimum integrated score of 1.9e-04. Before filtering, 25 257 possible candidates were 
data-mined from literature, linkage and homology sources. Of these, 13 mouse homologs were 
found to be related to bipolar disorder. Equation 8 shows the variance weight matrix used for 
prioritisation. Of the 292 training genes used to evaluate the DIG results, 37 genes were returned 
in the output table.  
 
   [0.702,      2.55𝑒 − 04 ,       0.298 ,       1.35𝑒 − 05]             (8) 
 
The top 41 genes, representing the top 5% of ranked genes from the DIG results, were analysed 
and shown in Table 3. Of these genes, eight were found to have no previous association to BPD. 
In particular, the huntingtin gene (HTT) was a surprising result, ranking 8
th
 in the DIG output. 
Enrichment analysis of the proteins encoded by these genes was performed. STRING showed no 
enrichment for PFAM or InterPro domains; however, protein interactions were highly enriched, 
with a p-value of 0.00. Figure 3 shows the 111 direct interactions that were observed among the 
top 41 proteins. Functional enrichment was also found in the three GO categories as well as 
known KEGG pathways. Table 4 lists the 5 most significant terms per functional category.  
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Table 3. Gene names of the top 41 genes for BPD as ranked by DIG. Previous association to BPD is also 
listed for each gene. “Training” indicates that the gene was used in the training gene set. 
Rank Gene symbol Gene name Association 
    
1 SLC6A4 Solute carrier family 6 (neurotransmitter transporter, 
serotonin), member 4 
Training 
2 BDNF Brain-derived neurotrophic factor Training 
3 HTR1A 5-hydroxytryptamine (serotonin) receptor 1A Yes 
4 DISC1 Disrupted in schizophrenia 1 Training 
5 DRD4 Dopamine receptor D4 Training 
6 SLC6A3 Solute carrier family 6 (neurotransmitter transporter, 
dopamine), member 3 
Training 
7 DTNBP1 Dystrobrevin binding protein 1 Training 
8 HTT Huntingtin No 
9 GSK3B Glycogen synthase kinase 3 beta Yes 
10 COMT Catechol-O-methyltransferase Yes 
11 HTR2A 5-hydroxytryptamine (serotonin) receptor 2A Yes 
12 TPH2 Tryptophan hydroxylase 2 Training 
13 TPH1 Tryptophan hydroxylase 1 Yes 
14 ANK3 Ankyrin 3, node of Ranvier (ankyrin G) Yes 
15 CYP2D6 Cytochrome P450, family 2, subfamily D, polypeptide 6 No 
16 DRD3 Dopamine receptor D3 Yes 
17 P2RX7 Purinergic receptor P2X, ligand-gated ion channel, 7 Yes 
18 ESR1 Estrogen receptor 1 No 
19 HTR1B 5-hydroxytryptamine (serotonin) receptor 1B Yes 
20 CNR1 Cannabinoid receptor 1 (brain) Yes 
21 AKT1 V-akt murine thymoma viral oncogene homolog 1 Yes 
22 IMPA2 Inositol(myo)-1(or 4)-monophosphatase 2 No 
23 S100B S100 calcium binding protein B Yes 
24 DRD1 Dopamine receptor D1 Yes 
25 ARNTL Aryl hydrocarbon receptor nuclear translocator-like Yes 
26 TH Tyrosine hydroxylase No 
27 CHRNA7 Cholinergic receptor, nicotinic, alpha 7 Yes 
28 XBP1 X-box binding protein 1 Yes 
29 CRY2 Cryptochrome 2 (photolyase-like) Yes 
30 DGKH Diacylglycerol kinase Yes 
31 NDUFV2 NADH dehydrogenase (ubiquinone) flavoprotein 2 Yes 
32 CRH Corticotropin releasing hormone Yes 
33 GRM7 Glutamate receptor, metabotropic 7 Yes 
34 TAAR6 Trace amine associated receptor 6 Yes 
35 DAO D-amino-acid oxidase Yes 
36 OPRM1 Opioid receptor, mu 1 No 
37 OXT Oxytocin, prepropeptide No 
38 ADRBK2 Adrenergic, beta, receptor kinase 2 Yes 
39 GABRB2 Gamma-aminobutyric acid (GABA) A receptor, beta 2 Yes 
40 ADRA2A Adrenergic, alpha-2A-, receptor No 
41 CCL2 Chemokine (C-C motif) ligand 2 Yes 
 




Figure 3. Protein-protein interactions between the top 41 ranked genes from the DIG analysis of BPD as 
mapped by STRING. Proteins circled in blue did not show previous association to BPD.  
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Table 4. The top 5 significantly enriched terms for several functional annotation categories when analysing 
















Category ID Term 
GO Biological 
process 
GO:0007611 learning or memory 
GO:0050890 cognition 
GO:0007613 memory 
GO:0051952 regulation of amine transport 
GO:0007610 behaviour 
   
GO molecular 
function 
GO:0043176 amine binding 
GO:0008144 drug binding 
GO:0035240 dopamine binding 
GO:0008227 G-protein coupled amine receptor activity 
GO:0043178 alcohol binding 
   
GO cellular 
compartment 
GO:0033267 axon part 
GO:0043005 neuron projection 
GO:0044463 cell projection part 
GO:0043195 terminal button 
GO:0030424 axon 
   
KEGG 
Pathway 
hsa04080 Neuroactive ligand-receptor interaction 
hsa04710 Circadian rhythm - mammal 
hsa04020 Calcium signalling pathway 
hsa00380 Tryptophan metabolism 
hsa04062 Chemokine signalling pathway 
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4 Discussion 
4.1 Prioritisation approach 
 
This study describes the development of DIG, a novel candidate gene prioritisation tool for 
complex disorders.  DIG applied a new approach to the ranking of candidate genes, which has not 
been used in existing candidate gene prioritisation tools. In this tool, literature, linkage, homology 
and sequence information is used to gather data on genes. Pseudogene information is used as a 
fifth source in order to filter candidates. DIG is able to both select and rank genes from a 
candidate search space that is not dependent on user-defined parameters.  
 
4.1.1 Overcoming current issues  
 
A major issue when analysing complex diseases with other available tools, is the requirement of 
training genes as an input. DIG does not rely on this guilt-by-association method to compare 
possible candidates, but rather overcomes this obstacle by analysing the variance of data for all 
genes that have any association to the disease, from various data sources. DIG then assumes that 
true susceptibility genes will score higher in disease-specific annotation than the rest of the 
genome. To account for genes in which annotation is missing, the integrated score is calculated 
such that genes are not penalised for incomplete information. This allows for the identification of 
novel genes that may be dissimilar to known training genes as well as supporting the discovery of 
poorly-characterised novel candidates. 
 
The performance of Posmed, GeneDistiller and Candid have shown dependence on the input 
entered by the user (Bornigen et al., 2012). DIG removes the need for the user to specify the 
weight matrix, unlike Candid. DIG also limits user-bias by the use of query expansion with DOID 
rather than requesting the user to list multiple query terms.  
 
4.1.2 Limiting false positives 
 
To the investigators’ knowledge, DIG is the first tool to include all linked loci for a disease in 
order to expand the candidate search space. This allows the analysis of all linkage data at once and 
also removes the need for the user to specify loci as an input. However, false positives are 
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frequent when extracting all genes from an associated chromosomal band, since only one variant 
within the region may be contributing towards the disease phenotype. Another source of false 
positives originates from text-mining which depends on co-occurrence of two terms, but cannot 
explain the relationship between them. For example if an article was specifying a negative 
disease-gene association. Articles that include more than one disease may also match a gene to the 
incorrect disease. To compensate for this, DIG uses stringent filters in order to limit candidates in 
a way that is not biased against poorly-studied genes. 
 
An issue not related to the performance of a tool, but rather its application, is that most tools do 
not sufficiently limit possible candidate genes. Geneticists are faced with a long list of genes from 
which they need to arbitrarily determine a cut-off value to then assay in case samples. DIG’s filter 
system limits the number of total genes ranked, but without bias towards well-studied genes. 
 
4.1.3 Further advantages of DIG 
 
DIG requires the user to input basic knowledge of their disease as an input. The tool uses the best 
performing parameters as default settings which is convenient for non-expert users; however, 
more advanced users are still able to fine tune the p-values at which to look for linkage data. Users 
are advised to use a less stringent linkage cut-off value for highly heterogenic diseases or for 
diseases that have decreased penetrance, and therefore have weak gene signals.  
 
Additional annotation such as tissue expression, SIFT and Polyphen scores allow users to 
critically evaluate the ranked genes. Furthermore, DIG interacts with databases directly, thereby 
remaining as up to date as possible. Local gene and association mappings will be regularly 
updated to maintain the accuracy of the system. DIG does not require registration or payment to 
make use of the tool, emphasising ease of access for the user. Although DIG has been evaluated 
with complex genetic diseases, this tool can also be applied to Mendelian or heterogenic diseases. 
 
4.2 Relative performance as a new tool 
 
Analysis of the test datasets showed that performance for asthma was worse than that for other 
test datasets. This is thought to be because asthma is relatively poorly studied compared to breast 
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cancer, type 2 diabetes and Alzheimer’s disease. Further tests of additional poorly-documented 
diseases may elucidate flaws in the DIG methodology that would need to be addressed.  
 
DIG demonstrates comparable performance when compared to PosMed, but Endeavour remains 
far more accurate according to TPR30, AUC and response rate. Further investigation shows that 
Endeavour does not filter any genes whatsoever, but simply ranks all possible candidates. This 
means response rate could not be anything less than 100% since no training genes would be 
excluded. TPR30 is also assumed to be inflated due to the vast amount of candidates, and thus 
much higher number of genes included in the top 30%. As a result, the performance measures for 
Endeavour are therefore better. Different performance indicators are perhaps needed to do an 
unbiased assessment of tools that filter candidate genes. 
 
4.3 Novel BPD candidates 
 
Of the 8 novel genes previously not associated to BPD, HTT was further investigated. The gene 
had 6 Pubmed articles linked to it, with a literature score of 1.127e-03. The high sequence score of 
0.597 is most likely due to the elongated CAG trinucleotide repeat expansions in exon-1 that are 
known to cause Huntington’s disease (Bano et al., 2011). 
 
One study reported an increased prevalence of manic symptoms in pre-symptomatic mutation 
carriers for Huntington’s disease as compared to non-carriers, but these symptoms did not 
completely fulfil DSM diagnostic criteria for BPD (Julien et al., 2007). Perlis et al. (2010) found 
that some individuals diagnosed with BPD also carried incompletely penetrant expanded HTT 
alleles.  
 
The involvement of HTT in BPD may be explained by a hypothesis that implicates a decrease in 
synaptic plasticity as the cause for the disease phenotype. Synaptic plasticity is defined as the 
variation in the ability of neurons to transmit a response (Hughes, 1958). Differences in the 
number of neurotransmitters within the synapse and the number of receptors on the post-synaptic 
membrane change plasticity of the neuron. Receptors are transiently stabilised on the synaptic 
membrane by interactions with scaffold proteins before being recycled to the intracellular 
compartment by endocytosis (Gerrow and Triller, 2010). Regulations of receptor-scaffold and 
scaffold–scaffold interactions are thus able to control synapse function.  
 
~ 38 ~ 
 
 
Previous BPD studies have found decreased expression of the synapsin family of proteins in the 
cingulate cortex and hippocampus (Eastwood and Harrison, 2001). These proteins are responsible 
for binding synaptic vesicles to the cytoskeleton, preventing their transport to the presynaptic 
membrane and subsequent neurotransmitter release. According to STRING, the putative function 
of HTT is listed as playing a role in microtubule-mediated transport or vesicle function. Should 
HTT have altered functioning or be down-regulated either due to CAG expansions or other 
mechanisms, similar effects on synaptic function could occur as noted in the above research. HTT 
has been shown to be most highly expressed in the cerebellar cortex, the neocortex, the striatum, 
and the hippocampal formation in the brain (Sayer et al., 2005). Additionally, this study shows 
that HTT interacts with BNDF (see figure 3), a major regulator of synaptic transmission and 
synaptic plasticity (http://www.string-db.org/). This evidence supports the notion that HTT may be 




The methodology behind DIG contains intrinsic errors that may be corrected in future designs. 
The reliance of webscraping puts the functionality of DIG at risk, should any of the websites it 
utilises change or be removed. For example, the source for linkage information, aBandApart, is 
currently not maintained. It was last updated in 2006; however, its use was still implemented for 
proof of concept in including all linked loci. It should be noted that since approximately 2001, 
linkage studies have rapidly declined due to the advent of GWAS and later NGS, thus it was 
assumed that linkage data would not be excessively outdated.  
 
The local file of Prospectr scores used to construct sequence information is also incomplete. A 
new, updated version was not compiled due to time constraints, but the effect is lessened due to 
the small weighting usually attributed to the sequence sub-score.  
 
The uneven coverage of the scientific literature, upon which DIG relies heavily, raises concerns 
about the ability of DIG to rank genes that have yet to be characterized in the scientific literature; 
however, the results from BPD suggest otherwise. It must also be noted that Gene2pubmed, 
dbSNP and homolog mappings are not dynamically queried, and will therefore need continual 
updates and maintenance. 
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4.5 Future work 
 
DIG has been designed in such a way that additional sources may be easily added to the tool to 
further increase its data-mining capabilities. Future work will aim to add gene expression data, 
association data, PPI and functional annotation including GO terms, transcription factor binding 
sites, pathway and protein domain enrichment to the DIG methodology. Supplementary figure 1 
demonstrates how these modules may be added to the DIG workflow. The implementation of 
search algorithms rather than webscraping is also advised for future revisions. To improve user 
functionality, the ability to export results from the website and increased speed of querying by 




We have introduced a new tool for candidate gene prioritisation, which combines literature, 
linkage, homolog, sequence and pseudogene data, allowing us to rank genes most likely involved 
in the aetiology of complex human genetic diseases. Validation with tissue expression and single 
nucleotide polymorphisms allow users to critically examine the ranked candidates. Performance 
indicators show that DIG is comparable to existing methods and is able to find novel disease-gene 
associations. In this study, the Huntingtin gene was shown to be a novel candidate gene to search 
for association to bipolar disorder. 
Data Integrated Genetics has wide application to the genetic research of complex diseases. Results 
may be followed up by genotyping and sequencing patient samples or even the creation of custom 
microarrays to evaluate a large number of variants in case and control cohorts. DIG represents an 
opportunity for geneticists to apply the vast amount of available biological data to a clinical 
research setting, ultimately facilitating research that may find possible treatment and alleviation of 
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Supplementary table 1. Training genes used for the evaluation of the DIG variance weight matrix using 
four complex diseases. 
 
 
Disease 
name input 
 
Training genes 
Breast 
cancer 
ENSG00000183765 
ENSG00000093010 
ENSG00000140465 
ENSG00000138061 
ENSG00000148795 
ENSG00000137869 
ENSG00000141736 
ENSG00000142208 
ENSG00000091831 
ENSG00000066468 
ENSG00000100697 
ENSG00000123908 
ENSG00000175324 
ENSG00000184451 
 
ENSG00000233209 
ENSG00000206237 
ENSG00000231939 
ENSG00000206302 
ENSG00000179344 
ENSG00000225824 
ENSG00000231286 
ENSG00000236884 
ENSG00000206240 
ENSG00000228080 
ENSG00000196126 
ENSG00000206306 
ENSG00000229074 
ENSG00000072571 
ENSG00000174775 
ENSG00000169083 
ENSG00000095015 
ENSG00000149311 
ENSG00000110628 
ENSG00000121879 
ENSG00000176907 
ENSG00000171862 
ENSG00000138376 
ENSG00000051180 
ENSG00000137077 
ENSG00000107562 
ENSG00000012048 
ENSG00000139618 
ENSG00000118046 
ENSG00000105329 
ENSG00000141510 
ENSG00000171940 
ENSG00000083093 
ENSG00000124151 
ENSG00000136492 
ENSG00000064012 
ENSG00000170836 
ENSG00000156735 
ENSG00000023287 
Type 2 
diabetes 
ENSG00000142330 
ENSG00000120915 
ENSG00000105221 
ENSG00000115159 
ENSG00000236418 
ENSG00000232062 
ENSG00000206305 
ENSG00000196735 
ENSG00000225890 
ENSG00000228284 
ENSG00000233209 
ENSG00000206237 
ENSG00000231939 
ENSG00000206302 
ENSG00000179344 
ENSG00000225824 
ENSG00000231286 
ENSG00000231679 
ENSG00000196101 
ENSG00000230463 
ENSG00000227357 
ENSG00000227826 
ENSG00000231021 
ENSG00000169047 
ENSG00000187486 
ENSG00000166035 
ENSG00000198763 
ENSG00000198786 
ENSG00000162992 
ENSG00000106331 
ENSG00000197594 
ENSG00000132170 
ENSG00000154415 
ENSG00000104918 
ENSG00000196396 
ENSG00000163581 
 
ENSG00000181856 
ENSG00000006071 
ENSG00000135100 
ENSG00000108753 
ENSG00000148737 
ENSG00000008196 
ENSG00000109501 
ENSG00000132570 
ENSG00000120833 
ENSG00000181092 
ENSG00000121653 
Asthma ENSG00000090376 
ENSG00000183134 
ENSG00000164265 
ENSG00000169252 
ENSG00000181019 
ENSG00000233095 
ENSG00000237216 
ENSG00000235680 
ENSG00000230413 
ENSG00000235346 
ENSG00000206506 
ENSG00000204632 
ENSG00000264751 
ENSG00000150540 
ENSG00000077238 
ENSG00000113302 
 
ENSG00000169194 
ENSG00000170745 
ENSG00000187258 
ENSG00000005381 
ENSG00000171195 
ENSG00000136147 
ENSG00000168229 
ENSG00000172156 
ENSG00000166888 
ENSG00000149021 
ENSG00000146070 
ENSG00000149451 
ENSG00000121691 
ENSG00000172057 
Alzheimer’s 
disease 
ENSG00000175899 
ENSG00000107331 
ENSG00000010704 
ENSG00000130203 
ENSG00000142192 
 
ENSG00000123384 
ENSG00000164867 
ENSG00000122861 
ENSG00000143801 
ENSG00000091513 
ENSG00000206439 
ENSG00000228978 
ENSG00000204490 
ENSG00000230108 
ENSG00000223952 
ENSG00000228321 
ENSG00000228849 
ENSG00000232810 
ENSG00000112715 
